Seeking Alpha

Amgen (AMGN) agrees to acquire deCODE Genetics, which analyzes the links between the genome and...

Amgen (AMGN) agrees to acquire deCODE Genetics, which analyzes the links between the genome and susceptibility to disease, in a deal that values the Icelandic company at $415M. deCODE Genetics has discovered genetic risks for dozens of illnesses, including cardiovascular problems and cancer. With the transaction not requiring regulatory approval, Amgen expects it to close by the end of the month. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs